These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 12108796)

  • 21. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults.
    Asherson P
    Expert Rev Neurother; 2005 Jul; 5(4):525-39. PubMed ID: 16026236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Family abuse of methylphenidate.
    Fulton AI; Yates WR
    Am Fam Physician; 1988 Aug; 38(2):143-5. PubMed ID: 3407585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study.
    Wilens TE; Biederman J; Lerner M;
    J Clin Psychopharmacol; 2004 Feb; 24(1):36-41. PubMed ID: 14709945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.
    Merkel RL; Kuchibhatla A
    Expert Opin Drug Saf; 2009 Nov; 8(6):655-68. PubMed ID: 19785509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between hyperactivity and executive cognitive functioning in childhood and substance use in early adolescence.
    Aytaclar S; Tarter RE; Kirisci L; Lu S
    J Am Acad Child Adolesc Psychiatry; 1999 Feb; 38(2):172-8. PubMed ID: 9951216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From the editors.
    Drake RE; Green AI
    J Dual Diagn; 2014; 10(3):107. PubMed ID: 25392283
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benzodiazepine Abuse in the Attention Deficit Hyperactivity Disorder: A Case Report.
    Lugoboni F; Morbioli L
    J Clin Psychopharmacol; 2018 Aug; 38(4):402-404. PubMed ID: 29901561
    [No Abstract]   [Full Text] [Related]  

  • 31. [Attention deficit disorder with hyperactivity (ADHD). Continuing symptom control with medium term methylphenidate treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2006 Nov; 29(11):415-6. PubMed ID: 17131689
    [No Abstract]   [Full Text] [Related]  

  • 32. Hyperactives as young adults: past and current antisocial behavior (stealing, drug abuse) and moral development [proceedings].
    Hechtman L; Weiss G; Perlman T
    Psychopharmacol Bull; 1981 Jan; 17(1):107-10. PubMed ID: 7232636
    [No Abstract]   [Full Text] [Related]  

  • 33. Flawed attention-deficit/hyperactivity disorder medication comparison.
    Adesman A
    Pediatrics; 2004 Oct; 114(4):1132; author reply 1132-3. PubMed ID: 15466129
    [No Abstract]   [Full Text] [Related]  

  • 34. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE; McBurnett K; Bukstein O; McGough J; Greenhill L; Lerner M; Stein MA; Conners CK; Duby J; Newcorn J; Bailey CE; Kratochvil CJ; Coury D; Casat C; Denisco MJ; Halstead P; Bloom L; Zimmerman BA; Gu J; Cooper KM; Lynch JM
    Arch Pediatr Adolesc Med; 2006 Jan; 160(1):82-90. PubMed ID: 16389216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modafinil treatment of amphetamine abuse in adult ADHD.
    Mann N; Bitsios P
    J Psychopharmacol; 2009 Jun; 23(4):468-71. PubMed ID: 18562425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study.
    Cox DJ; Merkel RL; Penberthy JK; Kovatchev B; Hankin CS
    J Am Acad Child Adolesc Psychiatry; 2004 Mar; 43(3):269-75. PubMed ID: 15076259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylphenidate.
    Nicolle FI
    Am Fam Physician; 1983 Nov; 28(5):27-8. PubMed ID: 6637755
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
    Prince JB
    Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse.
    Kuczenski R; Segal DS
    Biol Psychiatry; 2005 Jun; 57(11):1391-6. PubMed ID: 15950013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
    Le Heuzey MF; Vergnaud S; Mouren MC
    Arch Pediatr; 2006 Jan; 13(1):100-3. PubMed ID: 16239100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.